Philip Morris International upgraded by Societe Generale
$PM
Medicinal Chemicals and Botanical Products
Health Care
Societe Generale upgraded Philip Morris International from Sell to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/16/2025 | $140.00 | Overweight | Morgan Stanley |
| 3/5/2024 | Buy → Hold | Argus | |
| 2/13/2024 | Sell → Hold | Societe Generale | |
| 1/23/2024 | $105.00 → $86.50 | Buy → Sell | UBS |
| 11/16/2023 | $95.00 | Neutral | Redburn Atlantic |
| 6/20/2023 | $109.00 → $117.00 | Neutral → Buy | Citigroup |
| 4/14/2023 | $114.00 | Buy | Stifel |
| 3/30/2023 | $109.00 → $116.00 | Neutral → Overweight | JP Morgan |
Morgan Stanley initiated coverage of Philip Morris International with a rating of Overweight and set a new price target of $140.00
Argus downgraded Philip Morris International from Buy to Hold
Societe Generale upgraded Philip Morris International from Sell to Hold
8-K - Philip Morris International Inc. (0001413329) (Filer)
8-K - Philip Morris International Inc. (0001413329) (Filer)
8-K - Philip Morris International Inc. (0001413329) (Filer)
Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what
In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002
Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on January 13, 2025, to shareholders of record as of December 26, 2024. The ex-dividend date is December 26, 2024. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we
CCAA Plan Includes PMI's Canadian Affiliate RBH, Deconsolidated Since 2019; If RBH Reconsolidated, Expected to be Incremental to Key PMI Financial Metrics Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantiall
Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast at www.pmi.com/2024Q4earnings on Thursday, February 6, 2025, at 9:00 a.m. ET, to discuss its 2024 Fourth-Quarter and Full-Year financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The
Eight in 10 people believe misinformation undermines the adoption of critical innovations Nine in 10 people say it's important for governments to ensure public access to accurate information about innovations and to establish clear and fair regulations The challenges facing our world can overwhelm, but most people strongly believe in innovation's potential to address the most critical issues in the next 10–20 years, according to the results of a new independent survey commissioned by Philip Morris International Inc. (NYSE:PM). Conducted by Povaddo in 10 countries in Africa, the Americas, Asia, and Europe, the survey and resultant white paper "Innovation Under Pressure: Navigating Comple
FDA decision makes ZYN the first authorized nicotine pouch product Science-based decision affirms that ZYN nicotine pouches are a better alternative for adults who smoke or use other traditional tobacco products The U.S. Food and Drug Administration (FDA) today authorized ZYN nicotine pouches making ZYN the first and only authorized nicotine pouch in the United States. The FDA's authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+. "An estimated 45 million Americans regularly consume nicotine and abo
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)